Search
BIO-Europe: The FDA decision date for Hansa's IgG-inactivating therapy for kidney transplant patients is coming up on December 19th
CEO Renée Aguiar-Lucander describes the unmet need for a therapy like this, and discusses how Hansa has been preparing for this decision date well in advance. Coverage brought to you by
6 hours ago
Pareto Securities Healthcare Conference: Hansa Biopharma has a December 19 PDUFA date with FDA for its IgG depleting therapy that hopes to make more patients eligible for kidney transplant
CEO Renée Aguiar-Lucander describes the idea behind imlifidase and discusses the trial that led to the U.S. filing. Hansa has also recently confidentially filed for an IPO in the United States as well.
Sep 2
BIO International 2025: The new CEO of Sweden's Hansa Biopharma discusses potential uses of the company's IgG busting drug, imlifidase, including for kidney transplant and along with gene therapy
Renée Aguiar-Lucander describes the kidney transplant population that the therapy currently has conditional approval with the EMA for,...
Jun 18, 2025
.png){kind=logo}
